Cargando…
Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials
BACKGROUND: Funding and resources for low prevalent neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) are limited, and optimising their use is vital for efficient drug development. In this study, we review the design assumptions for pivotal ALS clinical trials with time-to-even...
Autores principales: | van Eijk, Ruben P A, Nikolakopoulos, Stavros, Roes, Kit C B, Middelkoop, Bas M, Ferguson, Toby A, Shaw, Pamela J, Leigh, P Nigel, Al-Chalabi, Ammar, Eijkemans, Marinus J C, van den Berg, Leonard H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902062/ https://www.ncbi.nlm.nih.gov/pubmed/31292200 http://dx.doi.org/10.1136/jnnp-2019-320998 |
Ejemplares similares
-
Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials
por: van Eijk, Ruben P A, et al.
Publicado: (2018) -
Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial
por: Al-Chalabi, Ammar, et al.
Publicado: (2019) -
Composite endpoint for ALS clinical trials based on patient preference: Patient-Ranked Order of Function (PROOF)
por: van Eijk, Ruben P A, et al.
Publicado: (2022) -
Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19
por: Al-Chalabi, Ammar, et al.
Publicado: (2021) -
Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis
por: Dreger, Marie, et al.
Publicado: (2022)